» Articles » PMID: 30197295

Differential MA, MA, and MA Demethylation Mediated by FTO in the Cell Nucleus and Cytoplasm

Overview
Journal Mol Cell
Publisher Cell Press
Specialty Cell Biology
Date 2018 Sep 11
PMID 30197295
Citations 393
Authors
Affiliations
Soon will be listed here.
Abstract

FTO, the first RNA demethylase discovered, mediates the demethylation of internal N-methyladenosine (mA) and N, 2-O-dimethyladenosine (mA) at the +1 position from the 5' cap in mRNA. Here we demonstrate that the cellular distribution of FTO is distinct among different cell lines, affecting the access of FTO to different RNA substrates. We find that FTO binds multiple RNA species, including mRNA, snRNA, and tRNA, and can demethylate internal mA and cap mA in mRNA, internal mA in U6 RNA, internal and cap mA in snRNAs, and N-methyladenosine (mA) in tRNA. FTO-mediated demethylation has a greater effect on the transcript levels of mRNAs possessing internal mA than the ones with cap mA in the tested cells. We also show that FTO can directly repress translation by catalyzing mA tRNA demethylation. Collectively, FTO-mediated RNA demethylation occurs to mA and mA in mRNA and snRNA as well as mA in tRNA.

Citing Articles

The Role of MA Modification in Autoimmunity: Emerging Mechanisms and Therapeutic Implications.

Xu L, Shen T, Li Y, Wu X Clin Rev Allergy Immunol. 2025; 68(1):29.

PMID: 40085180 DOI: 10.1007/s12016-025-09041-6.


Pulmonary Hypertension: Molecular Mechanisms and Clinical Studies.

Adu-Amankwaah J, You Q, Liu X, Jiang J, Yang D, Liu K MedComm (2020). 2025; 6(3):e70134.

PMID: 40066229 PMC: 11892029. DOI: 10.1002/mco2.70134.


m6A RNA methylation: a pivotal regulator of tumor immunity and a promising target for cancer immunotherapy.

Chen X, Yuan Y, Zhou F, Li L, Pu J, Jiang X J Transl Med. 2025; 23(1):245.

PMID: 40022120 PMC: 11871626. DOI: 10.1186/s12967-025-06221-y.


RNA-binding proteins as therapeutic targets in cancer.

Jungfleisch J, Gebauer F RNA Biol. 2025; 22(1):1-8.

PMID: 40016176 PMC: 11869776. DOI: 10.1080/15476286.2025.2470511.


The role of N(6)-methyladenosine (m6a) modification in cancer: recent advances and future directions.

Xie X, Fang Z, Zhang H, Wang Z, Li J, Jia Y EXCLI J. 2025; 24:113-150.

PMID: 39967906 PMC: 11830918. DOI: 10.17179/excli2024-7935.


References
1.
Yu B, Edstrom W, Benach J, Hamuro Y, Weber P, Gibney B . Crystal structures of catalytic complexes of the oxidative DNA/RNA repair enzyme AlkB. Nature. 2006; 439(7078):879-84. DOI: 10.1038/nature04561. View

2.
Maniatis T, REED R . The role of small nuclear ribonucleoprotein particles in pre-mRNA splicing. Nature. 1987; 325(6106):673-8. DOI: 10.1038/325673a0. View

3.
Ke S, Pandya-Jones A, Saito Y, Fak J, Vagbo C, Geula S . mA mRNA modifications are deposited in nascent pre-mRNA and are not required for splicing but do specify cytoplasmic turnover. Genes Dev. 2017; 31(10):990-1006. PMC: 5495127. DOI: 10.1101/gad.301036.117. View

4.
Zhou J, Wan J, Gao X, Zhang X, Jaffrey S, Qian S . Dynamic m(6)A mRNA methylation directs translational control of heat shock response. Nature. 2015; 526(7574):591-4. PMC: 4851248. DOI: 10.1038/nature15377. View

5.
Gerken T, Girard C, Tung Y, Webby C, Saudek V, Hewitson K . The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science. 2007; 318(5855):1469-72. PMC: 2668859. DOI: 10.1126/science.1151710. View